A process for manufacturing chromenes which are intended for the preparation of thermosetting resins, includes transforming an aromatic propargyl ether of general formula (I) into a chromene by flash vacuum thermolysis, at a temperature of between 300 and 600° C., at a pressure of between 4 and 10,000 Pa. It also concerns a process for preparing a material made of thermoset resin, including successively: a) implementation of the above process; b) polymerization of the reaction product obtained in a) so as to obtain the material made of thermoset resin; c) recovery of the material made of thermoset resin obtained in b).

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

A novel heterocyclic compound is provided. In particular, a novel heterocyclic compound which can improve the element characteristics of the light-emitting element is provided. The heterocyclic compound is represented by a general formula (G1)
DBqAr.sup.1.sub.nAr.sup.2-A(G1)
in which a substituted or unsubstituted dibenzo[f,h]quinoxalinyl group and a substituted or unsubstituted benzobisbenzofuranyl group are bonded to each other via a substituted or unsubstituted arylene group. In the general formula (G1), DBq represents a substituted or unsubstituted dibenzo[f,h]quinoxalinyl group, Ar.sup.1 represents a substituted or unsubstituted arylene group having 6 to 13 carbon atoms, n represents 0 or 1, Ar.sup.2 represents a substituted or unsubstituted arylene group having 6 to 13 carbon atoms, and A represents a substituted or unsubstituted benzobisbenzofuranyl group. When the arylene group represented by Ar.sup.1 and Ar.sup.2 has substituents, the substituents may be bonded to each other to form a ring.

A blue fluorescence dopant is characterized by the following structural formula: ##STR00001## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are, each independently, selected from, a hydrogen atom, a C1-C10 linear or branched alkyl group, a C1-C20 linear or branched alkyl group, a substituted or unsubstituted N-(phenylmethyl)imino group, a phenyl group, phenylamine, diphenylamine, phenyl pyridinylamine, bipyridinylamine, phenyl naphthylamine, binaphthylamine, phenyl phenanthrylamine, biphenanthrylamine, phenyl anthrylamine, bianthrylamine, phenanthridine, biphenyl, a pyridinyl group, a pyrimidinyl group, a quinolyl group and a triazinyl group. The blue fluorescence dopant disclosed in the present invention may facilitate to lower driving voltage and increase efficiency, brightness, heat stability, color purity, lifetime, etc. Further, an organic electroluminescent device using the blue fluorescence dopant has excellent performances of high efficiency and long lifetime.

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.